The economics of moonshots: Value in rare disease drug development.
作者信息
Yates Nathan, Hinkel Jennifer
机构信息
ForwardView Consulting, Clintwood, Virginia, USA.
The Data Economics Company, Los Angeles, California, USA.
出版信息
Clin Transl Sci. 2022 Apr;15(4):809-812. doi: 10.1111/cts.13270. Epub 2022 Mar 25.
Abstract
摘要
相似文献
1
The economics of moonshots: Value in rare disease drug development.登月计划的经济学：罕见病药物研发的价值
Clin Transl Sci. 2022 Apr;15(4):809-812. doi: 10.1111/cts.13270. Epub 2022 Mar 25.
2
Patients left behind: Rare dermatologic conditions miss the orphan drug development boom.被遗忘的患者：罕见皮肤病错过孤儿药研发热潮。
J Am Acad Dermatol. 2019 Oct;81(4):1025-1026. doi: 10.1016/j.jaad.2019.03.013. Epub 2019 Mar 14.
3
A decade of optimizing drug development for rare neuromuscular disorders through TACT.通过TACT为罕见神经肌肉疾病优化药物开发的十年。
Nat Rev Drug Discov. 2020 Jan;19(1):1-2. doi: 10.1038/d41573-019-00199-1.
4
Orphan drug development in China: progress and challenges.中国孤儿药的研发：进展与挑战
Lancet. 2019 Sep 28;394(10204):1127-1128. doi: 10.1016/S0140-6736(19)32179-8.
5
Think Rare, Think Inside and Out: Simple Question-Based Approach to Complex Rare Disease Drug Development.关注罕见病，内外兼修：用基于简单问题的方法应对复杂的罕见病药物研发。
J Clin Pharmacol. 2022 Dec;62 Suppl 2:S6-S11. doi: 10.1002/jcph.2173.
6
Improving the Study of New Medicines for Children With Rare Diseases.改善罕见病儿童新药的研究。
JAMA Pediatr. 2018 Jan 1;172(1):7-9. doi: 10.1001/jamapediatrics.2017.4012.
7
[The RARE 2017 meeting for companies developing products for rare patients].[2017年罕见病患者产品研发公司会议]
Med Sci (Paris). 2018 May;34 Hors série n°1:7. doi: 10.1051/medsci/201834s104. Epub 2018 Jun 18.
8
Case studies in rare disease small molecule discovery and development.罕见病小分子发现和开发的案例研究。
Bioorg Med Chem Lett. 2020 Nov 1;30(21):127462. doi: 10.1016/j.bmcl.2020.127462. Epub 2020 Aug 11.
9
Flexibility in the FDA approach to orphan drug development.美国食品药品监督管理局孤儿药开发方法的灵活性。
Nat Rev Drug Discov. 2017 Nov;16(11):737-738. doi: 10.1038/nrd.2017.151. Epub 2017 Sep 1.
10
Therapies for rare diseases: therapeutic modalities, progress and challenges ahead.罕见病治疗方法：治疗方式、进展及未来挑战。
Nat Rev Drug Discov. 2020 Feb;19(2):93-111. doi: 10.1038/s41573-019-0049-9. Epub 2019 Dec 13.
引用本文的文献
1
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups.溶瘤病毒和嵌合抗原受体T细胞基因治疗进展及治疗相关分组
Curr Issues Mol Biol. 2025 Apr 10;47(4):268. doi: 10.3390/cimb47040268.
2
CASCADE: a community-engaged action model for generating rapid, patient-engaged decisions in clinical research.CASCADE：一种社区参与的行动模型，用于在临床研究中做出快速、患者参与的决策。
BMC Med Res Methodol. 2025 Jul 1;25(1):168. doi: 10.1186/s12874-025-02565-7.
3
The role of public health in rare diseases: hemophilia as an example.公共卫生在罕见病中的作用：以血友病为例。
Front Public Health. 2025 Mar 20;13:1450625. doi: 10.3389/fpubh.2025.1450625. eCollection 2025.
4
Application of observational research methods to real-world studies for rare disease drugs: A scoping review protocol.观察性研究方法在罕见病药物真实世界研究中的应用：一项范围综述方案。
PLoS One. 2025 Mar 28;20(3):e0304540. doi: 10.1371/journal.pone.0304540. eCollection 2025.
5
Human-based complex models: their promise and potential for rare disease therapeutics.基于人类的复杂模型：它们在罕见病治疗中的前景与潜力。
Front Cell Dev Biol. 2025 Jan 27;13:1526306. doi: 10.3389/fcell.2025.1526306. eCollection 2025.
6
CASCADE: A Community-Engaged Action Model for Generating Rapid, Patient-Engaged Decisions in Clinical Research.CASCADE：一种社区参与行动模型，用于在临床研究中做出快速、患者参与的决策。
Res Sq. 2024 Aug 27:rs.3.rs-4790564. doi: 10.21203/rs.3.rs-4790564/v1.
7
Advanced Regenerative Medicines for Rare Diseases: A Review of Industry Sponsors Investment Motivations.罕见病的先进再生医学：行业赞助商投资动机的综述。
Ther Innov Regul Sci. 2024 Nov;58(6):1190-1199. doi: 10.1007/s43441-024-00690-x. Epub 2024 Sep 10.
8
Time for a new approach to drug development for rare systemic autoinflammatory diseases.是时候采用新方法来研发针对罕见系统性自身炎症性疾病的药物了。
Nat Rev Rheumatol. 2024 Jun;20(6):317-318. doi: 10.1038/s41584-024-01108-6.
9
Hemangiosarcoma in dogs as a potential non-rodent animal model for drug discovery research of angiosarcoma in humans.犬血管肉瘤作为人类血管肉瘤药物发现研究的潜在非啮齿类动物模型。
Front Oncol. 2023 Dec 7;13:1250766. doi: 10.3389/fonc.2023.1250766. eCollection 2023.
10
Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials.神经纤维瘤病和雪旺细胞瘤临床试验中生物标志物分析用生物样本采集和注释的推荐意见。
Clin Trials. 2024 Feb;21(1):40-50. doi: 10.1177/17407745231203330. Epub 2023 Oct 31.
本文引用的文献
1
Trends In Orphan Drug Spending And Out-Of-Pocket Spending Among US Children, 2013-18.2013 - 2018年美国儿童孤儿药支出及自付费用趋势
Health Aff (Millwood). 2020 Oct;39(10):1806-1811. doi: 10.1377/hlthaff.2020.00595.
2
How many rare diseases are there?有多少种罕见病？
Nat Rev Drug Discov. 2020 Feb;19(2):77-78. doi: 10.1038/d41573-019-00180-y.
3
Variation in US private health plans' coverage of orphan drugs.美国私人健康保险计划对罕见病药物覆盖范围的差异。
Am J Manag Care. 2019 Oct;25(10):508-512.
4
Orphan Cancer Drugs in the Era of Precision Medicine.精准医学时代的孤儿癌症药物。
JAMA Oncol. 2018 Nov 1;4(11):1481-1482. doi: 10.1001/jamaoncol.2018.3498.
5
Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period.评估《孤儿药法案》七年市场独占期的影响。
Health Aff (Millwood). 2018 May;37(5):732-737. doi: 10.1377/hlthaff.2017.1179.
6
Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group.罕见病术语与定义——一项全球性系统综述：药物经济学与结果研究国际协会（ISPOR）罕见病特别兴趣小组报告
Value Health. 2015 Sep;18(6):906-14. doi: 10.1016/j.jval.2015.05.008. Epub 2015 Aug 18.
7
Limits on use of health economic assessments for rare diseases.罕见病卫生经济评估的使用限制。
QJM. 2014 Mar;107(3):241-5. doi: 10.1093/qjmed/hcu016. Epub 2014 Jan 22.
8
Funding innovation for treatment for rare diseases: adopting a cost-based yardstick approach.为罕见病治疗创新提供资金：采用基于成本的衡量标准方法。
Orphanet J Rare Dis. 2013 Nov 16;8:180. doi: 10.1186/1750-1172-8-180.
Zotero 插件